TWD 70.6
(3.22%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 45.01 Million TWD | 195.23% |
2022 | 15.24 Million TWD | 5.0% |
2021 | 14.52 Million TWD | -46.46% |
2020 | 27.12 Million TWD | 64.21% |
2019 | 16.51 Million TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 64.72 Million TWD | 43.8% |
2024 Q2 | 101.69 Million TWD | 57.12% |
2023 Q4 | 45.01 Million TWD | 268.82% |
2023 FY | 45.01 Million TWD | 195.23% |
2023 Q3 | 12.2 Million TWD | -17.36% |
2023 Q2 | 14.76 Million TWD | -32.39% |
2023 Q1 | 21.84 Million TWD | 138.53% |
2022 FY | 15.24 Million TWD | 5.0% |
2022 Q4 | 9.15 Million TWD | 0.0% |
2021 FY | 14.52 Million TWD | -46.46% |
2020 FY | 27.12 Million TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
DIVA Laboratories, Ltd. | 2.53 Million TWD | -1677.804% |
Genetics Generation Advancement Corp. | 49.29 Million TWD | 8.688% |
Welgene Biotech Co.,Ltd. | 154.34 Million TWD | 70.836% |
Puriblood Medical Co., Ltd. | 51.64 Million TWD | 12.833% |
TFBS Bioscience Inc. | 131.77 Million TWD | 65.839% |